Assessing Treatment Options for ALK+ NSCLC
This video segment provides an in-depth discussion on the first-line use of lorlatinib for ALK-positive metastatic NSCLC, including clinical evidence from the phase 3 CROWN trial, the broader therapeutic landscape and alternative strategies, real-world insights on lorlatinib's performance, and key considerations for selecting among ALK inhibitors based on patient-specific factors.
Video content above is prompted by the following:
- Can you summarize the clinical evidence supporting lorlatinib use in the first-line treatment of ALK+ metastatic NSCLC?
- Could you highlight the primary efficacy outcomes from the phase 3 CROWN trial?
- How would you describe the current therapeutic landscape metastatic ALK+ NSCLC?
- What alternative treatment strategies could have been considered for this patient?
- Based on your clinical experience, how has lorlatinib performed in real-world practice?
- What advantages and challenges have you encountered when incorporating lorlatinib into your treatment protocols?
- How do you approach the selection process among the various available ALK inhibitors?
- What key factors influence your decision?
- In which specific patient subgroups would you lean towards using alectinib, lorlatinib, or brigatinib (the NCCN preferred treatments)?
Recent Videos
